GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2006

Xenomics Develops Test for AML

  • Xenomics developed a test for the detection of NPM gene mutations, a recently discovered genetic marker for acute myeloid leukemia (AML). Xenomics already holds the exclusive license for the use of that marker.

    “The NPM genetic marker is critically important to physicians because it can provide a diagnostic tool to identify an especially aggressive form of AML much more rapidly and effectively than conventional techniques,” explains David Tomei, Ph.D., CEO and co-founder. “This test developed by Xenomics is capable of detecting all known NPM mutations in DNA from bone marrow or blood cells of AML patients in one reaction with high sensitivity and specificity.

    “We are now preparing to move this test into the clinical setting,” adds Dr. Tomei.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?